Over the past 20 years, the available therapies for multiple sclerosis have expanded
exponentially. With several more agents likely to be approved for public funding in Australia …

The absence of pathological hallmarks of progressive multiple sclerosis (MS) in commonly
used rodent models of experimental autoimmune encephalomyelitis (EAE) hinders the …

Introduction: Despite recent progress, currently available therapies for relapsing remitting
multiple sclerosis (MS) are only partly effective, and their use is limited by tolerability and …

The failure of a majority of clinical trials in progressive multiple sclerosis (MS) has
highlighted the need to reconsider how these trials are designed and conducted, and many …

The pathological condition of multiple sclerosis (MS) relies on innate and adaptive immunity.
New types of agents that beneficially modify the course of MS, stopping the progression and …

The treatment of multiple sclerosis continues to evolve. However, even with the introduction
of B-cell depleting monoclonal antibodies, disability progression continues unabated since …

The increasing number of potent treatments for multiple sclerosis warrants screening for
infections. To investigate the prevalence of infections in two independent German patient …

Abstract Treatment of multiple sclerosis (MS) has improved considerably over the last
decade because of new insights into MS pathology and biotechnological advances. This …

In central nervous system (CNS) demyelinating disorders, such as multiple sclerosis (MS),
neuromyelitis optica (NMO) and related NMO-spectrum disorders (NMO-SD), a pathogenic …

The predominant clinical disease course of multiple sclerosis (MS) which can be treated
today by a variety of different disease-modifying treatments (DMT) is characterized by …